Information Provided By: 
Fly News Breaks for August 26, 2019
SGMO
Aug 26, 2019 | 07:08 EDT
H.C. Wainwright analyst Debjit Chattopadhyay started Sangamo Therapeutics with a Buy rating and $16 price target. The shares have further upside "as the Street recalibrates its view with an eye towards an expansive pipeline that leverages the company's core competence in ZFN-based genome editing, but in an ex vivo environment with potentially more predictable and controllable deliverables," Chattopadhyay tells investors in a research note.
News For SGMO From the Last 2 Days
There are no results for your query SGMO
